Market capitalization | $3.15m |
Enterprise Value | $-3.20m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.31 |
EV/Sales (TTM) EV/Sales | -5.42 |
P/S ratio (TTM) P/S ratio | 5.34 |
P/B ratio (TTM) P/B ratio | 0.44 |
Revenue growth (TTM) Revenue growth | -29.70% |
Revenue (TTM) Revenue | $590.00k |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Helius Medical Technologies Inc Class A:
1 Analyst has issued a forecast Helius Medical Technologies Inc Class A:
Jun '24 |
+/-
%
|
||
Revenue | 0.59 0.59 |
31%
31%
|
|
Gross Profit | 0.02 0.02 |
83%
83%
|
|
EBITDA | -12 -12 |
13%
13%
|
EBIT (Operating Income) EBIT | -12 -12 |
14%
14%
|
Net Profit | -8.84 -8.84 |
12%
12%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain's ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.
Head office | United States |
CEO | Dane Andreeff |
Employees | 22 |
Founded | 2014 |
Website | www.heliusmedical.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.